Table 1 Baseline demographic and clinical characteristics of patients overall and by initiation of first-line therapy (year)

Median age (range), years

68.0 (19.0, 88.0)

68.0 (37.0, 84.0)

68.0 (26.0, 85.0)

68.0 (24.0, 86.0)

67.0 (19.0, 87.0)

68.0 (40.0, 88.0)

68.0 (26.0, 85.0)

68.0 (19.0, 88.0)

Age group, years, n (%)

 <65

846 (38.9)

37 (36.3)

148 (39.4)

222 (37.9)

298 (41.6)

141 (35.8)

185 (38.7)

661 (39.0)

 ≥65 to <75

759 (34.9)

38 (37.3)

128 (34.0)

205 (35.0)

238 (33.2)

150 (38.1)

166 (34.7)

593 (34.9)

 ≥75

570 (26.2)

27 (26.5)

100 (26.6)

159 (27.1)

181 (25.2)

103 (26.1)

127 (26.6)

443 (26.1)

Sex, n (%)

 Male

1169 (53.7)

43 (42.2)

207 (55.1)

305 (52.0)

404 (56.3)

210 (53.3)

250 (52.3)

919 (54.2)

 Female

1006 (46.3)

59 (57.8)

169 (44.9)

281 (48.0)

313 (43.7)

184 (46.7)

228 (47.7)

778 (45.8)

Race, n (%)

 White

1670 (76.8)

82 (80.4)

283 (75.3)

444 (75.8)

563 (78.5)

298 (75.6)

365 (76.4)

1305 (76.9)

 Black or African American

288 (13.2)

16 (15.7)

56 (14.9)

69 (11.8)

92 (12.8)

55 (14.0)

72 (15.1)

216 (12.7)

 Asian

53 (2.4)

1 (1.0)

11 (2.9)

22 (3.8)

12 (1.7)

7 (1.8)

12 (2.5)

41 (2.4)

 American Indian or Alaska Native

24 (1.1)

0 (0)

3 (0.8)

6 (1.0)

9 (1.3)

6 (1.5)

3 (0.6)

21 (1.2)

 Native Hawaiian or Other Pacific Islander

2 (0.1)

0 (0)

0 (0)

1 (0.2)

1 (0.1)

0 (0)

0 (0)

2 (0.1)

 Other or Unknown Race

138 (6.3)

3 (2.9)

23 (6.1)

44 (7.5)

40 (5.6)

28 (7.1)

26 (5.4)

112 (6.6)

Ethnicity, n (%)

 Hispanic or Latino

50 (2.3)

0 (0)

9 (2.4)

14 (2.4)

17 (2.4)

10 (2.5)

9 (1.9)

41 (2.4)

 Not Hispanic or Latino

1924 (88.5)

88 (86.3)

333 (88.6)

523 (89.2)

634 (88.4)

346 (87.8)

421 (88.1)

1503 (88.6)

 Unknown

201 (9.2)

14 (13.7)

34 (9.0)

49 (8.4)

66 (9.2)

38 (9.6)

48 (10.0)

153 (9.0)

Smoking status, n (%)

 Yes (current or former smoker)

1912 (87.9)

85 (83.3)

313 (83.2)

501 (85.5)

647 (90.2)

366 (92.9)

398 (83.3)

1514 (89.2)

 No (never smoker)

263 (12.1)

17 (16.7)

63 (16.8)

85 (14.5)

70 (9.8)

28 (7.1)

80 (16.7)

183 (10.8)

Histology, n (%)

 Nonsquamous

1447 (66.5)

65 (63.7)

256 (68.1)

400 (68.3)

450 (62.8)

276 (70.1)

321 (67.2)

1126 (66.4)

   Adenocarcinoma only

1445 (66.4)

64 (62.7)

251 (66.8)

403 (68.8)

454 (63.3)

273 (69.3)

315 (65.9)

1130 (66.6)

 Squamous

457 (21.0)

24 (23.5)

70 (18.6)

120 (20.5)

167 (23.3)

76 (19.3)

94 (19.7)

363 (21.4)

 Adeno-squamous carcinoma

34 (1.6)

0 (0)

3 (0.8)

12 (2.0)

17 (2.4)

2 (0.5)

3 (0.6)

31 (1.8)

 NSCLC NOS

152 (7.0)

9 (8.8)

38 (10.1)

32 (5.5)

51 (7.1)

22 (5.6)

47 (9.8)

105 (6.2)

Stage, n (%)

 3

78 (3.6)

3 (2.9)

15 (4.0)

19 (3.2)

26 (3.6)

15 (3.8)

18 (3.8)

60 (3.5)

 4

2097 (96.4)

99 (97.1)

361 (96.0)

567 (96.8)

691 (96.4)

379 (96.2)

460 (96.2)

1637 (96.5)

Number of metastatic sites, n (%)

 0

23 (1.1)

2 (2.0)

4 (1.1)

6 (1.0)

7 (1.0)

4 (1.0)

6 (1.3)

17 (1.0)

 1

1404 (64.6)

64 (62.7)

239 (63.6)

361 (61.6)

443 (61.8)

297 (75.4)

303 (63.4)

1101 (64.9)

 2

504 (23.2)

22 (21.6)

90 (23.9)

149 (25.4)

173 (24.1)

70 (17.8)

112 (23.4)

392 (23.1)

 ≥3

173 (8.0)

8 (7.8)

32 (8.5)

50 (8.5)

69 (9.6)

14 (3.6)

40 (8.4)

133 (7.8)

 Missing

71 (3.3)

6 (5.9)

11 (2.9)

20 (3.4)

25 (3.5)

9 (2.3)

17 (3.6)

54 (3.2)

Location of metastases, n (%)

 Lung

433 (19.9)

24 (23.5)

81 (21.5)

107 (18.3)

141 (19.7)

80 (20.3)

105 (22.0)

328 (19.3)

 Brain

499 (22.9)

18 (17.6)

81 (21.5)

156 (26.6)

163 (22.7)

81 (20.6)

99 (20.7)

400 (23.6)

 Bone

649 (29.8)

23 (22.5)

113 (30.1)

188 (32.1)

228 (31.8)

97 (24.6)

136 (28.5)

513 (30.2)

 Liver

289 (13.3)

15 (14.7)

49 (13.0)

72 (12.3)

106 (14.8)

47 (11.9)

64 (13.4)

225 (13.3)

 Skin

11 (0.5)

2 (2.0)

2 (0.5)

1 (0.2)

3 (0.4)

3 (0.8)

4 (0.8)

7 (0.4)

 Lymph nodes

223 (10.3)

11 (10.8)

44 (11.7)

62 (10.6)

77 (10.7)

29 (7.4)

55 (11.5)

168 (9.9)

 Other

883 (40.6)

41 (40.2)

150 (39.9)

243 (41.5)

304 (42.4)

145 (36.8)

191 (40.0)

692 (40.8)

 None

23 (1.1)

2 (2.0)

4 (1.1)

6 (1.0)

7 (1.0)

4 (1.0)

6 (1.3)

17 (1.0)

 Missing

71 (3.3)

6 (5.9)

11 (2.9)

20 (3.4)

25 (3.5)

9 (2.3)

17 (3.6)

54 (3.2)

Evidence of visceral metastasis^a, n (%)

 Present

1716 (78.9)

80 (78.4)

301 (80.1)

463 (79.0)

568 (79.2)

304 (77.2)

381 (79.7)

1335 (78.7)

 Absent

459 (21.1)

22 (21.6)

75 (19.9)

123 (21.0)

149 (20.8)

90 (22.8)

97 (20.3)

362 (21.3)

Evidence of nonvisceral metastasis, n (%)

 Present

817 (37.6)

33 (32.4)

143 (38.0)

232 (39.6)

283 (39.5)

126 (32.0)

176 (36.8)

641 (37.8)

 Absent

1358 (62.4)

69 (67.6)

233 (62.0)

354 (60.4)

434 (60.5)

268 (68.0)

302 (63.2)

1056 (62.2)

ECOG PS groups, n (%)

 0 or 1

1408 (64.7)

66 (64.7)

212 (56.4)

358 (61.1)

486 (67.8)

286 (72.6)

278 (58.2)

1130 (66.6)

 2+

430 (19.8)

23 (22.5)

87 (23.1)

105 (17.9)

131 (18.3)

84 (21.3)

110 (23.0)

320 (18.9)

 Unknown

337 (15.5)

13 (12.7)

77 (20.5)

123 (21.0)

100 (13.9)

24 (6.1)

90 (18.8)

247 (14.6)

Patients by recorded line of therapy, n (%)

 1

2175 (100.0)

102 (100.0)

376 (100.0)

586 (100.0)

717 (100.0)

394 (100.0)

478 (100.0)

1697 (100.0)

 2

531 (24.4)

27 (26.5)

124 (33.0)

170 (29.0)

158 (22.0)

52 (13.2)

151 (31.6)

380 (22.4)

 3

136 (6.3)

7 (6.9)

47 (12.5)

48 (8.2)

31 (4.3)

3 (0.8)

54 (11.3)

82 (4.8)

 ≥4

38 (1.7)

1 (1.0)

18 (4.8)

13 (2.2)

6 (0.8)

0 (0)

19 (4.0)

19 (1.1)

History of autoimmune disease, n (%)

 Yes

33 (1.5)

2 (2.0)

7 (1.9)

8 (1.4)

9 (1.3)

7 (1.8)

9 (1.9)

24 (1.4)

 No

2142 (98.5)

100 (98.0)

369 (98.1)

578 (98.6)

708 (98.7)

387 (98.2)

469 (98.1)

1673 (98.6)

Patient Immunocompromised, n (%)^b,c

 Yes

240 (11.0)

16 (15.7)

46 (12.2)

63 (10.8)

73 (10.2)

42 (10.7)

62 (13.0)

178 (10.5)

 No

1935 (89.0)

86 (84.3)

330 (87.8)

523 (89.2)

644 (89.8)

352 (89.3)

416 (87.0)

1519 (89.5)

Use of immunosuppressive medication, n (%)

 Any

  Yes

385 (17.7)

26 (25.5)

72 (19.1)

109 (18.6)

125 (17.4)

53 (13.5)

98 (20.5)

287 (16.9)

  No

1790 (82.3)

76 (74.5)

304 (80.9)

477 (81.4)

592 (82.6)

341 (86.5)

380 (79.5)

1410 (83.1)

 Prednisone/prednisolone

   Yes

367 (16.9)

25 (24.5)

71 (18.9)

106 (18.1)

116 (16.2)

49 (12.4)

96 (20.1)

271 (16.0)

    Short-term use (<30 days)

200 (9.2)

13 (12.7)

39 (10.4)

64 (10.9)

69 (9.6)

15 (3.8)

52 (10.9)

148 (8.7)

    Long-term use (≥30 days)

225 (10.3)

16 (15.7)

45 (12.0)

61 (10.4)

65 (9.1)

38 (9.6)

61 (12.8)

164 (9.7)

   No

18 (0.8)

1 (1.0)

1 (0.3)

3 (0.5)

9 (1.3)

4 (1.0)

2 (0.4)

16 (0.9)

 Other immunosuppressive medications

   Yes

35 (1.6)

2 (2.0)

4 (1.1)

6 (1.0)

13 (1.8)

10 (2.5)

6 (1.3)

29 (1.7)

    Short-term use (<30 days)

8 (0.4)

0 (0)

0 (0)

1 (0.2)

7 (1.0)

0 (0)

0 (0)

8 (0.5)

    Long-term use (≥30 days)

23 (1.1)

1 (1.0)

4 (1.1)

4 (0.7)

6 (0.8)

8 (2.0)

5 (1.0)

18 (1.1)

   No

350 (16.1)

24 (23.5)

68 (18.1)

103 (17.6)

112 (15.6)

43 (10.9)

92 (19.2)

258 (15.2)

RET test recorded, n (%)

1076 (49.5)

39 (38.2)

146 (38.8)

242 (41.3)

355 (49.5)

294 (74.6)

185 (38.7)

891 (52.5)

 Positive

73 (3.4)

6 (5.9)

10 (2.7)

16 (2.7)

17 (2.4)

24 (6.1)

16 (3.3)

57 (3.4)

BRAF test recorded, n (%)

1280 (58.9)

39 (38.2)

171 (45.5)

320 (54.6)

440 (61.4)

310 (78.7)

210 (43.9)

1070 (63.1)

 Positive

108 (5.0)

5 (4.9)

15 (4.0)

25 (4.3)

37 (5.2)

26 (6.6)

20 (4.2)

88 (5.2)

MET exon 14 skipping mutation test, n (%)

1062 (48.8)

36 (35.3)

142 (37.8)

236 (40.3)

354 (49.4)

294 (74.6)

178 (37.2)

884 (52.1)

 Positive

0

0

0

0

0

0

0

0

RET, BRAF, or MET test recorded, n (%)

1307 (60.1)

40 (39.2)

178 (47.3)

330 (56.3)

447 (62.3)

312 (79.2)

218 (45.6)

1089 (64.2)

 Positive

179 (8.2)

10 (9.8)

25 (6.6)

41 (7.0)

53 (7.4)

50 (12.7)

35 (7.3)

144 (8.5)

PD-1/PD-L1 test recorded, n (%)

1566 (72.0)

55 (53.9)

258 (68.6)

424 (72.4)

517 (72.1)

312 (79.2)

313 (65.5)

1253 (73.8)

 Unknown

90 (4.1)

1 (1.0)

23 (6.1)

38 (6.5)

25 (3.5)

3 (0.8)

24 (5.0)

66 (3.9)

 Negative

498 (22.9)

20 (19.6)

72 (19.1)

124 (21.2)

159 (22.2)

123 (31.2)

92 (19.2)

406 (23.9)

 Positive

978 (45.0)

34 (33.3)

163 (43.4)

262 (44.7)

333 (46.4)

186 (47.2)

197 (41.2)

781 (46.0)

PD-1/PD-L1 expression level, n (%)

 PD-1/PD-L1 expression 1–49%^d

62 (2.9)

2 (2.0)

17 (4.5)

21 (3.6)

19 (2.6)

3 (0.8)

19 (4.0)

43 (2.5)

 PD-1/PD-L1 expression ≥50%^d

115 (5.3)

4 (3.9)

26 (6.9)

36 (6.1)

43 (6.0)

6 (1.5)

30 (6.3)

85 (5.0)